What is a biomarker? Sophie Paczesny, M.D., Ph.D., a professor at the Hollings Cancer Center at the Medical University of South Carolina and an internationally recognized expert on biomarkers for graft-versus-host disease (GvHD), explains.
First of four parts
Graft-versus-host disease (GvHD) is a side effect of allogeneic hematopoietic cell transplantation used to treat many types of blood cancers (leukemia, multiple myeloma) and other conditions related to the blood and the blood marrow. In simplified terms, GvHD occurs when the immune cells in the transplant (“the graft”) turn on and attack the cells of the recipient (“the host.”)
Sophie Paczesny, M.D.,Ph.D.
Allogeneic means the cells came from a donor, often a close relation. Autologous allogeneic hematopoietic cell transplantation — commonly referred to as bone marrow transplants or stem cell transplants — come from patients’ themselves.
GvHD is a recognized side effect, and researchers have made strides in understanding its causes and pathologic processes. Still, treating and managing GvHD remains a maze of choices.
In a review article published in Transplantation and Cellular Therapy in July, corresponding author Sophie Paczesny, M.D., Ph.D., and her colleagues explain how biomarkers could help patients and clinicians navigate that maze and possibly lead to treatment choices that would mean fewer side effects and better outcomes. Paczesny, a professor and chair of the Department of Microbiology and Immunology at the Hollings Cancer Center at the Medical of University of South Carolina, is an expert on hematopoietic cell transplantation, GvHD and biomarkers.
In this segment, Paczesny sets the table for a longer discussion with an introductory explanation of biomarkers. She stresses that it is an objective measurement that can aid diagnosis and prognosis. Measurement of substances in the blood are often involved, partly because it is relatively easy to get a sample of blood to test.
Today, the clade 2b outbreak has reached alarming proportions, with over 94,000 confirmed cases reported across 117 countries, including significant numbers in the U.S. and Brazil, and up to 103 deaths. The virus has been found to affect younger men who have sex with men, who are linked to high rates of HIV co-infection.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen